Biogen
Felzartamab
Immunoglobulin A Nephropathy (IgAN)
Countdown
328days
Phase 3 readout · May 31, 2027
What's at stake
Phase 3 trial results for Felzartamab in Immunoglobulin A Nephropathy (IgAN) are due May 31, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT06935357: Phase 3 trial, sponsor Biogen, drug Felzartamab. Primary completion date 2027-05-31 (estimated).”